Bristol-Myers Squibb Company
เพิ่มขึ้น

BMY Long

Trade Idea
Enter Long

- Ideal price is $64-$66

Stop Loss

- $64.4

Profit Target

- $70-$71


ARK fund is dumping Bristol-Myers Squibb (BMY), should you?

Yet another solid company with solid financials who is currently trading at 65.6% below estimated fair values. Earnings are forecasted to grow 30.88% per year. This stock also pays out a reliable dividend of 2.96%. Caution as there has been significant insider selling over the past 3 months. I plan on buying this at open tomorrow and holding for a few weeks or until price target is reached.

 For the six months ended 30 June 2021, Bristol-Myers Squibb Co revenues increased 9% to 22.78B. Net income totaled 3.08B vs. loss of 860M. Revenues reflect Prioritized Brands-Eliquis segment increase of 18% to5.68B, Prioritized Brands-Revlimid segment increase of 6%to 6.15B, United States segment increase of 9% to 14.4B,Europe segment increase of 11% to 5.24B.
bmylongbristol-myers-squibbChart PatternsTechnical IndicatorslongsetupTrend Analysis

และใน:

คำจำกัดสิทธิ์ความรับผิดชอบ